Management of the Cancer Patient With Infection and Neutropenia (original) (raw)
Related papers
Secondary Infections in Cancer Patients with Febrile Neutropenia
Turkish Journal of Hematology, 2012
Objective: Patients with neutropenia due to cancer chemotherapy are prone to severe infections. Cancer patients can experience >1 infectious episode during the same period of neutropenia. This study aimed to determine the etiological and clinical characteristics of secondary infectious episodes in cancer patients with febrile neutropenia and to identify the factors associated with the risk of secondary infectious episodes.
NEUTROPENIC FEVER IN ONCOLOGICAL PATIENTS: CHARACTERISTICS OF THE TREATMENT AND THE MAIN BIOCHEMICAL MARKERS (Atena Editora), 2022
Febrile neutropenia is a clinical complication in patients diagnosed with cancer and undergoing chemotherapy, which in turn leads to a condition of immunosuppression, making the patient vulnerable to infections to various microorganisms, and as a consequence the patient undergoing cancer treatment develops a more severe neutropenic condition. It is necessary to discuss the occurrence of febrile neutropenia in cancer patients, a measure adopted to prevent infectious conditions, with an inversely proportional relationship between infections by microorganisms and the decrease in the number of blood neutrophils in cancer patients, given the infectious context in which the cancer patient is exposed due to chemotherapy treatment, antibiotic therapy applied to patients with febrile neutropenia will be essential for professionals involved in the treatment of the patient for a positive recovery in the face of febrile neutropenia, thus avoiding a negative prognosis in the treatment of the cancer patient. The altered biochemical markers in cases of febrile neutropenia is also a parameter used for the follow-up of the oncological patient, clearly aiming at an approach regarding both the treatment of the oncological patient when he develops febrile neutropenia.
2021
Cl inical and Biochemical diagnosis of patients with febrile neutropenia attended Babylon Cancer Treatment center Diagnóstico clínico y bioquímico de pacientes con neutropenia febril atendidos en el centro de tratamiento del cáncer de Babylon Background: Febrile neutropenia define as an oral fever of more than 38.3°C or 38.0°C sustained for more than one hour, with absolute neutrophil count (ANC) should be <500/μL. FN associated with high rate of disease indisposition, mortality, affect chemotherapy price and doses, and leading to chemotherapy course interruptions, as well as affects the chemotherapy potency. Aim of study: This study was aimed to estimate the patients that have cancer and newly diagnosed with febrile neutropenia Patients and methods: A retrospective study that included one hundred and fifty patients already diagnosed with cancer who attended the outpatient clinic of Babylon Cancer Treatment Center, from 1 st of January 2020 to 1 st of January 2021. Results: From a total of 150 patients, age of patients ranged from 20-85 years, with mean age of 62.3±10.17 years, 63(42%) were males and 87(58%) were females. Breast cancer form 40%, as the most common solid cancers presented with febrile neutropenia, while head and neck cancer form 2%. We found 20% blood culture positive, and E. coli most bacterial isolated (40%), while 8.66% was positive urine culture and E. coli was form 84.6% also most commonly urine bacterial isolated, and only 2.66% sputum culture was positive and S. pneumonia is most common bacterial isolated (50%). 73.34% of patients presented with fever without localizing symptoms, while 12.66% of patients presented with respiratory system related symptoms. We found day 8 th after last cycle of chemotherapy was the most day of starting fever (28.66%). Conclusion: FN is a leading cause of cancer related death, early management is required to decrease rate of mortality.